News Novo fails to shrug off investor concern at Q2 update Novo Nordisk's better-than-expected second-quarter revenues can't outweigh worries about oral Wegovy growth and another CagriSema disappointment.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
News Novo's Wegovy pill cleared for weight loss in EU The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.
News UK approves Novo Nordisk's Wegovy pill Novo Nordisk's fast-growing Wegovy pill has been approved in the UK for weight loss, its first European market.
News France 'first EU country to cover obesity drugs' France's Health Minister has said that the country is the first in the EU to provide reimbursement coverage for GLP-1 weight-loss therapies.
News Oral Wegovy backed by CHMP at May meeting The CHMP recommended eight new medicines and 13 line extensions at its May meeting, including Novo Nordisk's oral weight loss therapy.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.